 |
42 Diseases |  |
111 Trials |
|
111 Trials |  |
1691 News |  |
| «12...20212223242526272829303132» |
- pegylated liposomal doxorubicin / Generic mfg., ifosfamide / Generic mfg.
Trial completion, Combination therapy, Metastases: Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P1, N=28, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed
- Trial initiation date, Metastases: Single Dose of Intravenous rhTNF-? and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Sep 17, 2012
P1, N=21, Suspended, Sponsor: Ludwig Institute for Cancer Research
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Jan 2013
- Enrollment open, PARP Biomarker: Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Sep 3, 2012
P1, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2012 --> Jan 2013 Not yet recruiting --> Recruiting
- | IMNN-001 / Imunon
New P1 trial, Combination therapy: Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer (clinicaltrials.gov) - Aug 26, 2012
P1, N=18, Recruiting, Sponsor: EGEN, Inc.
- Leukine (sargramostim) / Partner Therap
New P1 trial, Combination therapy: Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (clinicaltrials.gov) - Aug 23, 2012
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
- | Trial completion: Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 22, 2012
P2, N=40, Completed, Sponsor: Oncotherapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment closed: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 16, 2012
P1/2, N=31, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Terminated --> Active, not recruiting
- ||||| motolimod (VTX 2337) / BMS
New P2 trial, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 14, 2012
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
- New P1/2 trial, Metastases: ErbB2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 5, 2012
P1/2, N=15, Terminated, Sponsor: China Medical University Hospital
- Herceptin (trastuzumab) / Roche
Enrollment change, Metastases: CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer (clinicaltrials.gov) - Jul 26, 2012
P2, N=0, Withdrawn, Sponsor: National Cancer Institute, Naples
Terminated --> Active, not recruiting N=30 --> 0
- pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg.
Trial termination, Surgery: CASA: Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=77, Terminated, Sponsor: International Breast Cancer Study Group
N=30 --> 0 Active, not recruiting --> Terminated; Accrual rate was too low
- pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Surgery: CASA: Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=77, Terminated, Sponsor: International Breast Cancer Study Group
Active, not recruiting --> Terminated; Accrual rate was too low N=1296 --> 77
- Herceptin (trastuzumab) / Roche
Enrollment change, Combination therapy, Metastases: Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer (clinicaltrials.gov) - Jul 17, 2012
P1/2, N=30, Completed, Sponsor: University of Washington
N=1296 --> 77 N=50 --> 30
- Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer (clinicaltrials.gov) - Jul 17, 2012
P1/2, N=30, Completed, Sponsor: University of Washington
N=50 --> 30 Active, not recruiting --> Completed
- pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jul 16, 2012
P2, N=116, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
New P1/2 trial: PITCH: Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 9, 2012
P1/2, N=21, Completed, Sponsor: Leiden University Medical Center
- ||| Vectibix (panitumumab) / Amgen
Trial initiation date: PROVE: Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 1, 2012
P2, N=140, Recruiting, Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Oct 2011
- |||| Vectibix (panitumumab) / Amgen
Enrollment open: PROVE: Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 1, 2012
P2, N=140, Recruiting, Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
Initiation date: Jul 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial termination: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Jun 28, 2012
P1, N=1, Terminated, Sponsor: New Mexico Cancer Care Alliance
Not yet recruiting --> Recruiting Recruiting --> Terminated; Terminated due to inadequate rate of accrual.
- Avastin (bevacizumab) / Roche
Enrollment change: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Jun 28, 2012
P1, N=1, Terminated, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Terminated; Terminated due to inadequate rate of accrual. N=48 --> 1
- Trial completion, Combination therapy: A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 24, 2012
P1, N=3, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=48 --> 1 Active, not recruiting --> Completed
- seliciclib (CYC202) - Cyclacel, Cedars / Sinai
Trial withdrawal, Combination therapy, Metastases: Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jun 21, 2012
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Torisel (temsirolimus) / Pfizer
Trial completion: Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies (clinicaltrials.gov) - Jun 20, 2012
P1, N=28, Completed, Sponsor: Washington University School of Medicine
Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion: Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer (clinicaltrials.gov) - Jun 17, 2012
P2, N=15, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Trial suspension: INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (clinicaltrials.gov) - Jun 10, 2012
P3, N=588, Suspended, Sponsor: Mario Negri Institute for Pharmacological Research
Active, not recruiting --> Completed Recruiting --> Suspended
- | pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg.
Trial completion: S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Jun 10, 2012
P3, N=61, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Suspended Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: SAKK 24/06: Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 7, 2012
P2, N=43, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- carboplatin / Generic mfg.
Trial completion: Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer (clinicaltrials.gov) - May 28, 2012
P1/2, N=63, Completed, Sponsor: AGO Study Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| pegylated liposomal doxorubicin / Generic mfg.
Enrollment closed: CAPRICE: Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years (clinicaltrials.gov) - May 22, 2012
P2, N=66, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial termination, Monotherapy, Metastases: Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059) (clinicaltrials.gov) - May 14, 2012
P4, N=25, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Completed --> Terminated
- Zolinza (vorinostat) / Merck (MSD)
Trial withdrawal, Combination therapy: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Completed --> Terminated Suspended --> Withdrawn
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Suspended --> Withdrawn N=44 --> 0
- Enrollment closed, Post-transplantation: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (clinicaltrials.gov) - Apr 10, 2012
P2, N=45, Active, not recruiting, Sponsor: University of California, San Francisco
N=44 --> 0 Recruiting --> Active, not recruiting
- ||||||| Trial completion, Metastases: ET743-OVA-301: An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer (clinicaltrials.gov) - Apr 9, 2012
P3, N=672, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 22, 2012
P1, N=36, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed N=30 --> 36
- ||| Vynfinit (vintafolide) / Novartis
Enrollment change, Combination therapy: PRECEDENT: Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) (clinicaltrials.gov) - Mar 7, 2012
P2, N=162, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=30 --> 36 N=122 --> 162
- ||||| pegylated liposomal doxorubicin / Generic mfg., pomalidomide / Generic mfg.
Clinical: Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 27, 2012
P1/2, N=68, Recruiting, Sponsor: Oncotherapeutics
- ||| carlumab (CNTO 888) / J&J, MorphoSys
Trial completion, Combination therapy: A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors (clinicaltrials.gov) - Feb 26, 2012
P1, N=53, Completed, Sponsor: Centocor, Inc.
N=122 --> 162 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Trial initiation date, Combination therapy: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 18, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Apr 2012
- siplizumab (TCD601) / ITBMed, Rituxan (rituximab) / Roche
Enrollment closed: Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas (clinicaltrials.gov) - Feb 16, 2012
P1, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2012 --> Apr 2012 Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Combination therapy: Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma (clinicaltrials.gov) - Feb 4, 2012
P=N/A, N=30, Completed, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: UMCC 2004.047: Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma (clinicaltrials.gov) - Feb 4, 2012
P2, N=40, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jan 23, 2012
P1/2, N=31, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed N=45 --> 31
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 8, 2012
P1, N=42, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=45 --> 31 Recruiting --> Active, not recruiting
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment open, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Jan 2, 2012
P2, N=124, Recruiting, Sponsor: MolMed S.p.A.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
New P2 trial, Combination therapy: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 13, 2011
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
- New P1 trial, Metastases: Single Dose of Intravenous rhTNF-? and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Dec 8, 2011
P1, N=21, Suspended, Sponsor: Ludwig Institute for Cancer Research
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma
New P1 trial, Combination therapy: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 7, 2011
P1, N=18, Recruiting, Sponsor: Gynecologic Oncology Group
- pegylated liposomal doxorubicin / Generic mfg., nintedanib / Generic mfg.
New P1/2 trial, Combination therapy: Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer (clinicaltrials.gov) - Dec 4, 2011
P1/2, N=41, Suspended, Sponsor: Hoosier Oncology Group
- Avastin (bevacizumab) / Roche
Enrollment change: Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) (clinicaltrials.gov) - Nov 22, 2011
P2, N=46, Completed, Sponsor: New Mexico Cancer Care Alliance
Not yet recruiting --> Recruiting N=18 --> 46